Daval cleared to start Ph IIb Aimspro study

3 December 2007

Daval International , a UK private company, says that the Medicines and Healthcare products Regulatory Agency (MHRA) and the independent review board have approved a London-based Phase IIb trial of Aimspro, its hyperimmune caprine serum derivative.

This double-blind, cross-over study will seek to detect a beneficial effect on bladder function in patients with secondary progressive multiple sclerosis, following open-label observations over several years in a number of informed consent, compassionate-use basis patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight